Seer, Inc.

NASDAQ:SEER

Biotechnology

Healthcare
$1.44 +0.29%

+$0.01 today

Market cap
$80.37M
Beta
1.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.26
52W Low $1.65High $2.41

Volume 0.23M

Average 0.32M

SEER Interest Expense

Cost of servicing the company's debt during the period.

Seer, Inc.NASDAQ: SEER

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense remains negative

Q1 FY2026 interest expense was $0, compared with $0 a year earlier. Trailing-twelve-month interest expense was $0.

Context

  • Interest expense amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Interest expense increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Interest Expense vs competitors

How SEER compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Interest expense amounts to 0.0% of revenue for SEER, versus a peer median of 0.0%.
SEER Competitors
Interest Expense for SEER and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KYMRKymera Therapeutics, Inc.LTM Jun 2026$211K USD-29.4%+12.3%0.2%
PHVSPharvaris N.V.LTM Sep 2026€87.82K EUR———
MOLNMolecular Partners AGLTM Mar 2026CHF 45.01K CHF+45.1%-69.7%—
SEERSeer, Inc.LTM Mar 2026$0 USD——0.0%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$0 USD——0.0%
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$0 USD———
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$0 USD———
SANASana Biotechnology, Inc.LTM Mar 2026$0 USD———
STTKShattuck Labs, Inc.LTM Mar 2026$0 USD——0.0%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
LYELLyell Immunopharma, Inc.LTM Mar 2026$0 USD——0.0%
PEPGPepGen Inc.LTM Mar 2026$0 USD———
QSIQuantum-Si incorporatedLTM Mar 2026$0 USD——0.0%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$0 USD———
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$0 USD——0.0%
NKTXNkarta, Inc.LTM Mar 2026$0 USD———
MNOVMediciNova, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding SEER) —+7.9%-28.7%0.0%

Competitors are the stored peer set for SEER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.39M14.69M15.18M13.95M16.12M
Cost of Revenue6.77M14.3M13.73M7.12M14.22M
Gross Profit(374K)384K1.45M6.83M1.9M
Gross Margin-5.8%2.6%9.5%49.0%11.8%
Research & Development29.12M45.8M47.44M50.59M37.77M
Selling, General & Admin42.2M52.63M58.95M56.57M42.58M
Operating Expenses71.32M98.43M106.39M106.93M80.35M
Depreciation & Amortization3.56M5.9M5.58M6.18M6.1M
EBITDA(67.61M)(87.07M)(80.7M)(80.33M)(67.3M)
EBITDA Margin-1057.3%-592.9%-531.5%-575.9%-417.5%
Operating Income(71.7M)(98.04M)(104.94M)(100.1M)(78.45M)
Operating Margin-1121.3%-667.6%-691.2%-717.7%-486.7%
Interest Income326K4.6M17.76M16.67M11.52M
Interest Expense22K0000
Other Income / Expenses527K5.08M18.67M13.6M5.05M
Income Before Tax(71.17M)(92.97M)(86.28M)(86.5M)(73.4M)
Pre-Tax Margin-1113.1%-633.1%-568.3%-620.2%-455.4%
Income Tax Expense00098K201K
Net Income(71.17M)(92.97M)(86.28M)(86.6M)(73.6M)
Net Margin-1113.1%-633.1%-568.3%-620.9%-456.6%
EPS (Basic)(1.13)(1.42)(1.35)(1.39)(1.28)
EPS (Diluted)(1.13)(1.42)(1.35)(1.39)(1.28)
Weighted Avg Shares60.86M62.43M63.85M62.35M57.45M
Weighted Avg Shares (Diluted)60.86M62.43M63.85M62.35M57.45M

Seer, Inc.

NASDAQ:SEER

Intrinsic Alpha fair value

Locked

Current Price

$1.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.